NCT00851461

Effect of Goserelin (Zoladex®) in Spinal and Bulbar Muscular Atrophy

Effect of Goserelin (Zoladex®) in Spinal and Bulbar Muscular Atrophy in Thai Patients

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: Ramathibodi Hospital · Academic / Other
• Sex: Male
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

This is a therapeutic trial study to demonstrate whether Goserelin, a LHRH agonist has benefit in SBMA Objective: 1. To study effects of Goserelin to clinical course of patients with spinal and bulbar muscular atrophy in Thailand 2. To demonstrate physiological and pathological changes in treated patients with Goserelin. 3. To assess tolerability and adverse effect of Goserelin therapy

Conditions

• Spinobulbar Muscular Atrophy
• Kennedy's Disease

Interventions

Type	Name	Description
DRUG	Goserelin	Goserelin 10.8 mg SC every 3 months
PROCEDURE	Electrophysiologic study	Nerve conduction study Electromyogram
PROCEDURE	tissue biopsy	skin and muscle biopsy before and after treatment every year

Timeline

• Start date: 2008-04-01
• Primary completion: 2011-11-01
• Completion: 2013-11-01
• First posted: 2009-02-26
• Last updated: 2015-05-21

Locations

1 site across 1 country: Thailand